Rheumatoid arthritis (RA) is considered a chronic disease that cannot be cured. Biologic
agents have enabled good therapeutic successes; however, the response to biologic …

Introduction: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory
approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and …

Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …

Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management
recommendations addressing the most recent developments in the field. Methods An …

Objectives To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in
RAPID-PsA (NCT01087788), an ongoing Phase 3 trial in patients with psoriatic arthritis …

Background To date, head-to-head trials comparing the efficacy and safety of biological
disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in …

Objective CONCERTO was a randomised, double-blind, parallel-armed study of
methotrexate (MTX) in combination with adalimumab to assess whether an increasing trend …

The five TNF inhibitors currently approved for the treatment of RA are characterised by
differences in their molecular structures, half-lives, administration routes, dosing intervals …

Objective Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of
rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti …

Despite recommendations suggesting that biological and targeted synthetic disease-
modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with …